Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor.

[1]  K. Nakajima,et al.  Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation , 2003, Circulation.

[2]  H. Pijl,et al.  Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. , 2003, Metabolism: clinical and experimental.

[3]  M. Matsuda,et al.  Angiopoietin-like Protein 3 Mediates Hypertriglyceridemia Induced by the Liver X Receptor* , 2003, Journal of Biological Chemistry.

[4]  M. Shimamura,et al.  A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice Published, JLR Papers in Press, April 2, 2003. DOI 10.1194/jlr.M300031-JLR200 , 2003, Journal of Lipid Research.

[5]  M. Matsuda,et al.  Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. , 2003, Biochemical and biophysical research communications.

[6]  Theresa Zhang,et al.  Regulation of the angiopoietin-like protein 3 gene by LXR Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200367-JLR200 , 2003, Journal of Lipid Research.

[7]  Kenichi Yoshida,et al.  ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase* , 2002, The Journal of Biological Chemistry.

[8]  G. Camenisch,et al.  ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * , 2002, The Journal of Biological Chemistry.

[9]  T. Fujiwara,et al.  Angptl3 regulates lipid metabolism in mice , 2002, Nature Genetics.

[10]  G. Reaven.  Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia , 2002, Diabetes, obesity & metabolism.

[11]  D. Capuzzi,et al.  Lipid disorders in type 1 and type 2 diabetes. , 2001, Clinics in laboratory medicine.

[12]  P. Cullen.  Evidence that triglycerides are an independent coronary heart disease risk factor. , 2000, The American journal of cardiology.

[13]  M. Gibney,et al.  The Impact of Postprandial Lipemia in Accelerating Atherothrombosis , 2000, Journal of cardiovascular risk.

[14]  Y. Iwamoto,et al.  Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. , 2000, Diabetes care.

[15]  H. Ginsberg.  Insulin resistance and cardiovascular disease. , 2000, The Journal of clinical investigation.

[16]  S. Wattler,et al.  Identification of a mammalian angiopoietin-related protein expressed specifically in liver. , 1999, Genomics.

[17]  S. Phaneuf,et al.  Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. , 1999, Metabolism: clinical and experimental.

[18]  P. Elwood,et al.  Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. , 1999, Atherosclerosis.

[19]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[20]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[21]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[22]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[23]  T. Yoshioka,et al.  Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. , 1991, Metabolism: clinical and experimental.

[24]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[25]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[26]  R. Unger.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0870 Minireview: Weapons of Lean Body Mass Destruction: The Role of Ectopic Lipids in the Metabolic Syndrome , 2022 .